Financial Enhancement Group LLC Kintara Therapeutics, Inc. Transaction History

Financial Enhancement Group LLC

  • $569 Million
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Oct 14, 2021
SELL
$0.82 - $2.3 $1,025 - $2,875
-1,250 Closed
0 $0
Q2 2021

Aug 10, 2021
BUY
$1.26 - $2.4 $1,575 - $3,000
1,250 New
1,250 $3,000

About Kintara Therapeutics, Inc.

KTRA Quotes by TradingView
  • Ticker KTRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 80,807,296
  • Market Cap $17.8M
  • Description
  • Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme,...
More about KTRA
Track This Portfolio

Track Financial Enhancement Group LLC Portfolio

Follow Financial Enhancement Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Financial Enhancement Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Financial Enhancement Group LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email